OBJECTIVE: To investigate the effect of efavirenz on the ketoconazole pharmacokinetics in HIV-infected patients. METHODS:Twelve HIV-infected patients were assigned into a one-sequence, two-period pharmacokinetic interaction study. In phase one, the patients received 400 mg of ketoconazole as a single oral dose on day 1; in phase two, they received 600 mg of efavirenz once daily in combination with 150 mg of lamivudine and 30 or 40 mg of stavudine twice daily on days 2 to 16. On day 16, 400 mg of ketoconazole was added to the regimen as a single oral dose. Ketoconazole pharmacokinetics were studied on days 1 and 16. RESULTS: Pretreatment with efavirenz significantly increased the clearance of ketoconazole by 201%. C(max) and AUC(0-24) were significantly decreased by 44 and 72%, respectively. The T ((1/2)) was significantly shorter by 58%. CONCLUSION:Efavirenz has a strong inducing effect on the metabolism of ketoconazole.
RCT Entities:
OBJECTIVE: To investigate the effect of efavirenz on the ketoconazole pharmacokinetics in HIV-infectedpatients. METHODS: Twelve HIV-infectedpatients were assigned into a one-sequence, two-period pharmacokinetic interaction study. In phase one, the patients received 400 mg of ketoconazole as a single oral dose on day 1; in phase two, they received 600 mg of efavirenz once daily in combination with 150 mg of lamivudine and 30 or 40 mg of stavudine twice daily on days 2 to 16. On day 16, 400 mg of ketoconazole was added to the regimen as a single oral dose. Ketoconazole pharmacokinetics were studied on days 1 and 16. RESULTS: Pretreatment with efavirenz significantly increased the clearance of ketoconazole by 201%. C(max) and AUC(0-24) were significantly decreased by 44 and 72%, respectively. The T ((1/2)) was significantly shorter by 58%. CONCLUSION:Efavirenz has a strong inducing effect on the metabolism of ketoconazole.
Authors: Rob E Aarnoutse; Karin J T Grintjes; Denise S C Telgt; Michael Stek; Patricia W H Hugen; Peter Reiss; Peter P Koopmans; Yechiel A Hekster; David M Burger Journal: Clin Pharmacol Ther Date: 2002-01 Impact factor: 6.875
Authors: Er-jia Wang; Karen Lew; Christopher N Casciano; Robert P Clement; William W Johnson Journal: Antimicrob Agents Chemother Date: 2002-01 Impact factor: 5.191
Authors: S M Clarke; F M Mulcahy; J Tjia; H E Reynolds; S E Gibbons; M G Barry; D J Back Journal: Br J Clin Pharmacol Date: 2001-03 Impact factor: 4.335
Authors: John G Gerber; Susan L Rosenkranz; Carl J Fichtenbaum; Jose M Vega; Amy Yang; Beverly L Alston; Susan W Brobst; Yoninah Segal; Judith A Aberg Journal: J Acquir Immune Defic Syndr Date: 2005-07-01 Impact factor: 3.731
Authors: C Brass; J N Galgiani; T F Blaschke; R Defelice; R A O'Reilly; D A Stevens Journal: Antimicrob Agents Chemother Date: 1982-01 Impact factor: 5.191
Authors: William D Figg; Sukyung Woo; Wenhui Zhu; Xiaohong Chen; A Seun Ajiboye; Seth M Steinberg; Douglas K Price; John J Wright; Howard L Parnes; Philip M Arlen; James L Gulley; William L Dahut Journal: J Urol Date: 2010-06 Impact factor: 7.450
Authors: Kristin H Busse; Elizabeth Formentini; Raul M Alfaro; Joseph A Kovacs; Scott R Penzak Journal: J Acquir Immune Defic Syndr Date: 2008-08-15 Impact factor: 3.731